At Trethera, we are advancing innovative therapies across oncology and autoimmune diseases. Our robust pipeline reflects our commitment to addressing unmet medical needs and improving patient outcomes.
TRE-515 is an orally taken pill under development for autoimmune diseases and in clinical trials for solid tumors. As a first-in-class drug, TRE-515 blocks a key enzyme called deoxycytidine kinase (dCK) that has been implicated in abnormal cell proliferation.
Broad Uses
TRE-515 is a first-in-class therapy aimed at treating ADEM, optic neuritis, MS, cancer, lupus, Crohn’s disease and more —a unique, diversified opportunity within a single drug.
More Shots on Goal
Each clinical trial we conduct opens new doors for success, with each disease indication creating multiple pathways to impact and changing patient lives.
